N※N

ProMIS Neurosciences Announces Private Placement Financing

ProMIS Neurosciences Bolsters Pipeline with Major Private Placement Financing

In a significant move to fuel its innovative research into neurodegenerative diseases, ProMIS Neurosciences Inc., a biotechnology company specializing in precision medicine for conditions like Alzheimer's disease, has announced a substantial private placement financing. The Toronto-based firm, listed on both the Nasdaq and the Toronto Stock Exchange under the ticker PMN, revealed plans to raise up to approximately $20.3 million through this non-brokered offering. This development, detailed in a recent press release, underscores the company's commitment to advancing its proprietary platform for targeting misfolded proteins, which are implicated in a range of debilitating neurological disorders.

At the heart of this financing is ProMIS's strategy to accelerate the clinical development of its lead therapeutic candidate, PMN310. This monoclonal antibody is designed to selectively target toxic oligomers of amyloid-beta, a key pathological feature in Alzheimer's disease. Unlike broader-spectrum therapies that may inadvertently affect healthy proteins, ProMIS's approach leverages computational modeling and proprietary algorithms to create highly specific treatments. The funds from this placement are earmarked primarily for advancing PMN310 into Phase 1b clinical trials, with potential expansion into other programs targeting diseases such as amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).

The private placement involves the issuance of units priced at $1.05 each, with each unit comprising one common share and one warrant to purchase an additional share at $1.30 within five years. This structure not only provides immediate capital but also offers investors a pathway to further participation in the company's growth. ProMIS has already secured commitments for about $7.3 million in the initial closing, with the potential to reach the full $20.3 million through additional tranches. Notably, the offering is being led by prominent institutional investors, including Great Point Partners, LLC, a healthcare-focused investment firm, alongside participation from existing shareholders and company insiders. This vote of confidence from sophisticated investors highlights the perceived value in ProMIS's differentiated technology platform.

Eugene Williams, Chairman and CEO of ProMIS Neurosciences, expressed optimism about the financing in the announcement. "This private placement represents a pivotal step in our journey to deliver transformative therapies for patients suffering from neurodegenerative diseases," he stated. "With this funding, we are well-positioned to advance PMN310 through critical clinical milestones, bringing us closer to addressing the unmet needs in Alzheimer's treatment." Williams emphasized the company's unique ProMIS™ platform, which uses machine learning and biophysical techniques to identify disease-specific epitopes on misfolded proteins. This precision targeting aims to minimize off-target effects, a common pitfall in earlier generations of neurodegenerative therapies.

To fully appreciate the significance of this announcement, it's essential to contextualize ProMIS Neurosciences within the broader landscape of biotechnology and neurodegenerative research. Founded in 2008 and headquartered in Cambridge, Massachusetts, with operations in Toronto, ProMIS has built its reputation on a foundation of scientific innovation. The company's name itself—ProMIS, standing for "Protein Misfolding Induced by Stress"—reflects its core focus on the role of misfolded proteins in disease progression. These proteins, when they aggregate abnormally, form toxic structures that damage neurons, leading to cognitive decline in Alzheimer's, motor dysfunction in ALS, and other symptoms in related conditions.

Alzheimer's disease, in particular, remains one of the most pressing global health challenges. Affecting over 50 million people worldwide, with numbers projected to triple by 2050 according to the World Health Organization, it represents a massive unmet medical need. Current treatments, such as cholinesterase inhibitors and the recently approved anti-amyloid antibodies like lecanemab and donanemab, offer symptomatic relief or modest disease modification but come with limitations, including side effects like brain swelling and the need for intravenous administration. ProMIS's PMN310 seeks to improve upon these by focusing exclusively on the most toxic forms of amyloid-beta, potentially offering better efficacy and safety profiles.

The financing comes at a crucial time for ProMIS, following positive preclinical data and regulatory milestones. In recent years, the company has presented compelling evidence at major conferences, such as the Alzheimer's Association International Conference, demonstrating PMN310's ability to cross the blood-brain barrier and neutralize toxic oligomers without binding to non-pathogenic forms of the protein. This selectivity could reduce the risk of adverse events seen in other therapies, such as amyloid-related imaging abnormalities (ARIA), which have plagued competitors.

Beyond PMN310, ProMIS's pipeline includes other promising candidates. For instance, PMN267 targets ALS by addressing misfolded SOD1 proteins, while PMN400 focuses on alpha-synuclein aggregates in MSA and Parkinson's disease. The influx of capital from this placement will not only support PMN310's advancement but also enable exploratory work on these assets, potentially diversifying the company's portfolio and mitigating risks associated with single-asset dependency.

From a financial perspective, this private placement is a strategic alternative to more dilutive public offerings, especially in the current volatile market for biotech stocks. The Nasdaq Biotechnology Index has experienced fluctuations amid economic uncertainties, inflation concerns, and shifting investor sentiment toward high-risk, high-reward sectors like neurodegeneration. By opting for a private placement, ProMIS avoids the immediate market pressures of a public raise while securing funds from believers in its long-term vision. The involvement of insiders in the financing further signals strong internal confidence, as executives and board members are putting their own capital on the line.

Investors and analysts will be watching closely for upcoming catalysts, including the initiation of the Phase 1b trial for PMN310, expected in the coming months. Success in this trial could pave the way for partnerships with larger pharmaceutical companies, additional funding rounds, or even accelerated regulatory pathways under programs like the FDA's Breakthrough Therapy Designation.

However, challenges remain. The biotech industry is fraught with high failure rates in clinical trials, particularly for neurodegenerative diseases where biomarkers and endpoints can be elusive. ProMIS must navigate regulatory hurdles, competition from giants like Biogen and Eli Lilly, and the need for robust data to validate its platform's superiority. Moreover, the five-year warrant exercise period introduces long-term dilution risks if the stock performs well, though this is balanced by the potential upside for early investors.

In the broader context of global health, this financing announcement is more than a corporate milestone—it's a beacon of hope for millions affected by neurodegenerative diseases. As populations age, the economic burden of these conditions, estimated at over $1 trillion annually worldwide, continues to grow. Innovations like those from ProMIS could shift the paradigm from mere management to potential cures or preventions.

Looking ahead, ProMIS Neurosciences appears poised for growth. With a strengthened balance sheet and a clear path forward, the company is exemplifying how targeted biotechnology can address some of medicine's toughest challenges. As Williams noted, "Our mission is to harness the power of precision medicine to change the course of neurodegenerative diseases." If successful, this private placement could mark the beginning of a new chapter not just for ProMIS, but for the field at large.

This development also reflects a resilient biotech sector, where companies like ProMIS continue to attract investment despite market headwinds. By focusing on science-driven solutions, ProMIS is positioning itself as a leader in the fight against Alzheimer's and beyond. Stakeholders, from patients to investors, will undoubtedly follow the company's progress with keen interest, hopeful that this funding will translate into meaningful therapeutic breakthroughs.

(Word count: 1,048)

Read the Full Toronto Star Article at:
[ https://www.thestar.com/globenewswire/promis-neurosciences-announces-private-placement-financing/article_5739c785-60c2-5312-95fd-67e188ac909c.html ]